Tailor-made therapy of multi-resistant tuberculosis

Tailor-made therapy of multi-resistant tuberculosis
First author Hans-Peter Grobbel explains some results. Credit: Research Center Borstel, the Leibniz Lung Center

Globally, tuberculosis is the most common bacterial infectious disease leading to death. The pathogen causing tuberculosis, Mycobacterium tuberculosis, has a number of peculiarities. One is that it is growing very slowly. While other typical pathogens, such as pneumococcal and pseudomonads, can already be identified by their growth in the microbiological laboratory in the first 72 hours, several weeks usually pass before tuberculosis bacteria grow in the lab. Thus it often takes one to two months before the efficacy of individual medicines can be tested.

However, these efficacy tests are essential for the effective treatment of multidrug-resistant (MDR-TB), which is becoming increasingly common. In these cases, the pathogen has become resistant, i.e. insensitive, to the best tuberculosis drugs, rifampicin and isoniazid. This is due to changes in the genome, so-called mutations, which almost always occur at the same points in the genome. Treatment of MDR-TB is protracted, costly and frequently associated with side effects.

For the selection of antibiotics in a , doctors have so far depended on the results of the test after cultivation. "Currently, 15 drugs are available for second-line therapy, of which at least four are used in combination," explains Prof. Christoph Lange, coordinator of the clinical study at the Research Center Borstel.

In order to accelerate the choice of the most effective , DZIF scientists at the Research Center Borstel, led by Prof. Stefan Niemann, have created a catalog of mutations in the genetic material of that permits prediction of antibiotic resistances of the against all drugs. Unlike many other bacteria, the genetic material of the tuberculosis bacteria hardly changes over time. The genome of tuberculosis bacteria carries roughly 4.4 millions of building blocks (base pairs) that store the information for about 4,000 genes.

Hans-Peter Grobbel, and predoctoral DZIF fellow in Christoph Lange's team, supported by his fellow student Niklas Köhler, Professor Matthias Merker, Dr. Sönke Andres and Dr. Harald Hoffmans, has examined the results of antibiotic resistance predictions through overall genome analyses. Using tuberculosis bacteria from70 patients with MDR-TB treated at the Borstel Department of Medicine, researchers compared the molecular prediction of antibiotic resistance with actual cultural test results. They were contributed by Prof. Florian Maurer, Head of the National Reference Laboratory for Tuberculosis Bacteria in Borstel. The scientists also examined whether reliable combinations of drugs for the treatment of MDR-TB could be compiled based on the prediction of the bacteria´s genetic material.

"Ninety-nine per cent of all drugs in combination therapies that we have assembled based on the results of molecular predictions from the genetic material of tuberculosis bacteria are also effective according to traditional microbiological antibiotic resistance testing," Grobbel explains. By now, the molecular methods are both cheap and fast. Ideally, patients can already receive tailored MDR-TB treatment in the first week of their tuberculosis diagnosis.


Explore further

Tuberculosis: New biomarker indicates individual treatment duration

More information: Hans-Peter Grobbel et al, Design of multidrug-resistant tuberculosis treatment regimens based on DNA sequencing, Clinical Infectious Diseases (2021). DOI: 10.1093/cid/ciab359
Journal information: Clinical Infectious Diseases

Provided by German Center for Infection Research
Citation: Tailor-made therapy of multi-resistant tuberculosis (2021, May 3) retrieved 24 June 2021 from https://medicalxpress.com/news/2021-05-tailor-made-therapy-multi-resistant-tuberculosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
4 shares

Feedback to editors

User comments